Clinical Trial
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
- NCT ID
- NCT07285434
- Status
- Enrolling by invitation
- Study Type
- Interventional
- Lead Sponsor
- Biogenea Pharmaceuticals Ltd.
- Enrollment
- 90 participants
- Start
- Feb 2026
- Estimated Completion
- Feb 2030
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans
Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.
© 2026 Health AI Central. All rights reserved.
Source: https://healthaicentral.com/research/science-discovery/trials/NCT07285434